Εκπαιδευτικά προγράμματα
Λίστα αντικειμένων
Presenter: Dr Liga
Participants:Prof. Spyridonidis, Prof. Marangos, Dr Spyridis, Dr
Aggelinas
The update of WHO CLASSIFICATION OF HEMATOLOGICAL MALIGNANCIES was
presented.
Presenter: Prof:Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Aggelinas
Goal of the educational session is to understand the role of DPB1
mismatched in allo Tx. We discussed their level of expression
and their alloreactivity as is scored in the TCE algorithm.
We also discussed a new proposed methodology which defines the DPB1
alloreactivity...
Scope: To update the current treatment management of CLL in the
elderly.
Presenter: Dr Spyridis
Participants: Prof. Spyridonidis, Dr Liga, Dr Aggelinas.
Based on a case we discussed the current treatment guidelines
for essential thrombocythemia. Dr Spyridis presented the current
How I treat Blood paper.
Presenter: Dr Spyridis
Participants: Prof: Spyridonidis, Dr Liga, Dr Aggelinas
We discussed a recent review of the Treatment Options for
Carbapenem- Resistant Gram-Negative Infections.
We additionally reviewed our current policy in treating these
infections and implemented a new policy.
Presenter: Prof. Marangos
Participants: Prof. Spyridonidis, Dr Spyridis, Dr Liga, Dr
Aggelinas.
We discussed novel insights regarding the pathophysiology of CRS
after CART therapy published in Nature Medicine. Activation of
macrophages plays a major role.
Goal: The Hellenic experience of the use of BV in relapsed HD
was presented. The need for transplant after achieving some disease
control was discussed.
Presenter: Prof. Spyridonidis.
Participants: Dr Liga, Dr Spyridis, Dr Aggelinas.
Goal: We discussed the legislation about SEC and other terms
such as GRID. The legislation was presented, especially the
specific issue regarding BMT units in Greece which will be
presented in EU TE Compenidum.
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Aggelinas, Dr
Triantafyllou.
Goal: To understand how PTCY works. We reviewed the current
literature of PTCY after related or unrelated Tx. We discussed that
the data are premature in order to adopt this strategy.
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Aggelinas, Dr
Triantafyllou.
Goal: To understand how PTCY works. We reviewed the current
literature of PTCY after related or unrelated Tx. We discussed that
the data are premature in order to adapt this strategy.
Presenter: Prof. Spyridonidis.
Participants: Dr Liga, Dr Spyridis, Dr Aggelinas, Dr
Triantafyllou.
Goal: To present the analysis of our transplant strategy.
Results of the analysis of about 100 transplants is shown. Dr Maria
Liga presented us her database. Prof. Spyridonidis explained how
the data were analysed. The decision to add Cellcept in the case of
a...
Goal: The use of TKIs post transplant to prevent relapse. A
recent paper describing how sorafenob in mflt3 mutant AML promotes
the local GVL effect is presented.
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Aggelinas
Goal: Our current research paper in CLL published in Blood
Advances was presented. Further goals were discussed.
Presenter: Prof. Spyridonidis.
Participants: Dr Liga, Dr Spyridis, Dr Aggelinas.
Goal: To learn how to calculate EFS,OS, TRM, how to create
Kaplan Meier curves and CI curves. The difference between CI and
Kapolan Meier was discussed.
Corresponding literature from ALPWP EBMT is provided.
Presenter: Prof. Spyridonidis.
Participants: Dr Liga, Dr Spyridis, Dr Aggelinas.
Goal: To learn the differences between RIC, RTC, MAC, NMA,
etc.
Corresponding literature is provided.
Presenter: Prof. Spyridonidis.
Participants: Dr Liga, Dr Spyridis, Dr Aggelinas
Goal: To learn how to deceide whether we should get an older
person to transplant. Literature and cases are presented.
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Aggelinas, Dr
Triantafyllou.
Goal: To understand the structure of donor registries. Learn
corresponding terminology.
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Aggelinas, Dr
Triantafyllou.
Goal:To learn about Bite, inotuzumab and CART therapies.
Presenter: Prof. Spyridonidis.
Participants: Dr Liga, Dr Spyridis, Dr Aggelinas
Goal: Which graft is better to use in haplo PTCY transplant?
Dr Liga presented the current literature. We deceide the
following policy CR-1 BM, advanced disease PBSC.
Presenter: Dr Liga
Participants: Prof. Spyridonidis, Dr Spyridis, Dr Aggelinas, Dr
Triantafyllou.
Βρέθηκαν 402 αποτελέσματα. Σελίδα 15 από 21